385 related articles for article (PubMed ID: 22067390)
1. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
[TBL] [Abstract][Full Text] [Related]
3. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
4. Common cancer stem cell gene variants predict colon cancer recurrence.
Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ
Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173
[TBL] [Abstract][Full Text] [Related]
5. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.
Yamanaka T; Oki E; Yamazaki K; Yamaguchi K; Muro K; Uetake H; Sato T; Nishina T; Ikeda M; Kato T; Kanazawa A; Kusumoto T; Chao C; Lopatin M; Krishnakumar J; Bailey H; Akagi K; Ochiai A; Ohtsu A; Ohashi Y; Yoshino T
J Clin Oncol; 2016 Aug; 34(24):2906-13. PubMed ID: 27325854
[TBL] [Abstract][Full Text] [Related]
6. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
7. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Lyman GH; Cosler LE; Kuderer NM; Hornberger J
Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
[TBL] [Abstract][Full Text] [Related]
8. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
[TBL] [Abstract][Full Text] [Related]
9. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP
J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406
[TBL] [Abstract][Full Text] [Related]
10. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
Venook AP; Niedzwiecki D; Lopatin M; Ye X; Lee M; Friedman PN; Frankel W; Clark-Langone K; Millward C; Shak S; Goldberg RM; Mahmoud NN; Warren RS; Schilsky RL; Bertagnolli MM
J Clin Oncol; 2013 May; 31(14):1775-81. PubMed ID: 23530100
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
[TBL] [Abstract][Full Text] [Related]
12. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
[TBL] [Abstract][Full Text] [Related]
13. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
[TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
16. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Meyerhardt JA; Heseltine D; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Thomas J; Nelson H; Whittom R; Hantel A; Schilsky RL; Fuchs CS
J Clin Oncol; 2006 Aug; 24(22):3535-41. PubMed ID: 16822843
[TBL] [Abstract][Full Text] [Related]
17. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N
J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
